Allegra Asthma Claim Would Be Key Defense Vs. Forced OTC Switch – Aventis
This article was originally published in The Tan Sheet
Aventis' Allegra experimental asthma indication would be the best defense against a forced OTC switch of the antihistamine, Chief Operating Officer Richard Markham told analysts during Aventis' R&D day in London June 18
You may also be interested in...
FDA's review of safety and birth registry data to determine whether Schering-Plough's Claritin (loratadine) could be linked to hypospadia is expected to take approximately three months
Failure to approve Claritin OTC for chronic idiopathic urticaria would perpetuate off-label use of non-prescription drugs to treat hives, Schering-Plough told FDA's Nonprescription Drugs Advisory Committee at a meeting in Bethesda, Md. April 22
Schering-Plough does not expect to receive three years of Hatch/Waxman exclusivity for its supplemental NDAs for OTC Claritin (loratadine)